The Bethesda System for Reporting Thyroid Cytopathology is the most widely used classification system for the reporting of thyroid fine-needle aspiration cytology (FNAC) specimens. However, the "atypical" category ("atypia of undetermined significance" [AUS] or "follicular lesion of undetermined significance" [FLUS]) continues to cause diagnostic and therapeutic dilemmas. The objectives of this study were to describe the differential malignancy rates of FNACs diagnosed as AUS/FLUS based on nuclear or architectural atypia and to assess the significance of demographic and ultrasonographic features in predicting malignancy in this category. METHODS: A retrospective review was performed of all thyroid FNACs between 2008 and 2014 that were diagnosed as AUS/FLUS at a tertiary referral center in Singapore.
INTRODUCTION
The worldwide incidence of thyroid neoplasms has risen steadily over the last few decades, 1 and thyroid nodules are among the most common clinical presentations. 2 The reported prevalence of thyroid nodules in the adult population is from 4% to 7%, however, less than 5% are malignant. 2 To make an accurate preoperative diagnosis of thyroid nodules, fine-needle aspiration (FNA) cytology (FNAC) has become the standard of care. The technique of FNAC was first introduced in Scandinavia in the 1950s and gained worldwide popularity in the 1980s. 3 Over the years, it has gained significance as a quick, safe and relatively simple method to differentiate malignant from benign thyroid nodules. It is also minimally invasive; 4 cost effective; 5 and, at the same time, highly reliable, with an accuracy rate as high as 97%; 3 thus, it is regarded as the gold-standard first-line diagnostic test in the evaluation of thyroid nodules. 6 The Bethesda System for Reporting Thyroid Cytopathology (TBSRTC) was proposed in 2007 and classifies results into 6 diagnostic categories, each with a suggested risk of malignancy and specific recommendations for subsequent management. 7 The objective of TBSRTC was to standardize the reporting of FNAC findings and thereby facilitate the communication of results between pathologists and treating physicians that are unambiguous and clinically helpful. 7 Since its inception, it has been demonstrated that TBSRTC improves the quality of FNAC reporting, reducing ambiguous diagnoses and decreasing surgery rates for benign lesions. 8 This has culminated in its widespread, international acceptance and its endorsement by the American Thyroid Association (ATA) as part of the revised 2015 ATA guidelines. A second edition of TBSRTC is scheduled to be released in 2018. Despite the benefits of FNAC and the Bethesda system, limitations still exist, the most significant of which are cases that fall into the "atypical" category-termed "atypia of undetermined significance (AUS)" or "follicular lesion of undetermined significance (FLUS) ." The malignancy rates for this category vary widely among institutions, ranging from 15.7% 9 to 81%. 10 There also exists great heterogeneity in the cytology subgroups within this category, with significantly different risks of malignancy. 11 Several studies propose that this category should be subclassified based on the presence of nuclear atypia to reflect this, [11] [12] [13] a viewpoint supported by the International Panel for the second edition of TBSRTC. 14 However, subclassification has neither been widely adopted 12 nor included in the revised 2015 ATA guidelines. 15 This category continues to cause significant diagnostic and therapeutic challenges, because a general consensus has not been reached among physicians and institutions on optimal management. 16 Therefore, the objective of this study was to assess the rate of thyroid malignancies at a tertiary referral center in cases classified as AUS/FLUS using the Bethesda System. In particular, we aimed to study malignant outcomes after subclassification of cases into those that exhibited nuclear atypia versus those with architectural atypia. The significance of demographic and ultrasonographic features in predicting malignant outcomes in this group also was assessed.
MATERIALS AND METHODS
The database of the Department of Pathology, National University Hospital, Singapore, was searched for all thyroid FNACs that were diagnosed as "atypical" between January 1, 2008 and December 31, 2014. This is a tertiary referral center. The Institutional Review Board approved this study (IRB no.: 2015/00898). Informed consent for research was obtained from all patients involved.
All FNACs were performed by experienced clinicians, pathologists, or radiologists using a 23-gauge to 25-gauge French needle, and three-quarters were performed under ultrasound guidance. Typically, from 2 to 5 passes were made. Adequacy was determined by rapid on-site evaluation, which was routinely performed by cytotechnologists assessing air-dried smears stained with Hemacolor (EMD Millipore, Billerica, Mass). Alcohol-fixed smears were also prepared for each sample and stained with Papanicolaou stain for final cytopathologic interpretation. Smears were interpreted by qualified anatomic pathologists, according to the TBSRTC. 7 "Atypical" cases included nodules with architectural, nuclear, and/or lymphoid atypia. Nodules in which architectural atypia, but no significant nuclear atypia, was present included those with some (but not predominant) microfollicular or trabecular patterns and/or focal nuclear crowding to an extent that was qualitatively or quantitatively insufficient for a diagnosis of neoplasia or malignancy; eg, low cellularity, suboptimal cellular preservation, or admixed with flat honeycomb sheets (Fig. 1) . Nodules that fit these criteria and had a significant Hurthle cell Original Article population were included within the architectural atypia category and designated "FLUS Hurthle."
Nodules with atypical nuclear features included those with qualitatively or quantitatively insufficient features for "suspicious for malignancy," ie, some degree of nuclear enlargement, grooves, abnormal chromatin pattern, or nuclear overlapping and crowding and rare, poorly formed inclusions (Figs. 2 and 3 ). Other atypical cases also included atypical lymphoid populations, in which the diagnosis of lymphoma could not be excluded. This subcategory was designated "AUS/FLUS (lymphoid)."
Patient demographics, follow-up data (including repeat FNAC results evaluated by pathologists in the same department), preoperative ultrasonographic features, and final histopathology results were retrieved. The ultrasound features evaluated included number of nodules, nodule size, laterality, echogenicity (described as hyperechoic, isoechoic, hypoechoic, or heterogeneous), presence of calcifications (described as none, microcalcifications [<1 mm], or macrocalcifications [1 mm]), presence of internal vascularity, margins (described as well defined or irregular), and nodule components (described as solid without cystic component, mixed containing cystic component, or purely cystic). These preoperative ultrasound features of specific thyroid nodules and radiologic-guided FNAC reports were meticulously matched with the nodule descriptions on final histology to ensure that the final histology results of resected nodules corresponded fully to the nodules that underwent FNAC.
Malignant outcomes included papillary, follicular, medullary, or anaplastic thyroid carcinoma as well as thyroid lymphomas on final histology. Incidental papillary microcarcinomas were not considered malignant on follow-up, according to international guidelines. 15 The rate of malignancy within the "atypical" category was also separately calculated for cases with nuclear atypia and architectural atypia (inclusive of Hurthle cell lesions) to determine malignant outcomes in each subcategory.
Only patients who underwent surgical intervention and had a final histopathologic diagnosis were considered in the final analysis to calculate the overall malignancy rate for the AUS/FLUS category. Patients who underwent repeat FNAC were followed and analyzed according to FNAC follow-up protocol. 15 Statistical analysis was performed using SPSS version 21 (IBM Corporation, Armonk, NY). Ordinate demographic and ultrasonographic variables were assessed for significance using chi-square analysis with Yates correction. Continuous variables were evaluated using 2-tailed t tests with the level of significance set at P < .05. For the multivariate analysis, a logistic regression model was used to determine independent predictors of malignancy. 
RESULTS
In total, 309 of 4815 FNACs analyzed during the study period were diagnosed as "atypical" (AUS/FLUS according to TBSRTC). Of these, the patients included 73 men (23.6%) and 236 women (76.4%), and their mean age ( 6 standard deviation) was 54.7 6 15.2 years.
The Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) diagram in Figure  4 illustrates the outcomes of the 309 patients in the study. One hundred twenty-five patients (40.5%) underwent immediate surgical resection. Among the remaining 184 patients, 73 (39.7%) underwent a repeat FNAC, and 111 of 309 patients (35.9%) received no further intervention or follow-up. The spectrum of benign outcomes encountered in the final histopathologic diagnoses in our study included colloid goiter, follicular adenoma, Hurthle cell adenoma, Hashimoto thyroiditis, and thyroid cysts.
The PRISMA diagram in Figure 5 illustrates the results of those who underwent repeat FNA. Forty-nine of 73 patients (67.1%) who had 1 or more repeat FNACs had a more definitive diagnosis. Of these, 44 FNAs (89.8%) were benign, 4 (8.2%) were suspicious for malignancy, and 1 (2%) had frank malignancy. Twelve patients (16.4%) underwent surgical resection after repeat FNAC. Our analysis also indicated that 22 of 39 patients (56.4%) who had nuclear atypia at the initial FNAC had a more definitive diagnosis after 1 or more repeat FNACs compared with 23 of 34 patients (67.6%) who had architectural atypia, although these results were not statistically different (P 5 .73). Among patients who had only architectural atypia, the rate of a benign diagnoses with repeat FNACs was 70.6% (24 of 34) compared with those who had nuclear atypia (48.7%; 19 of 39; P 5 .05). Table 1 indicates that, of all the demographic and ultrasonographic features, only irregularity of margins was significant in predicting malignancy on both univariate (P < .01) and multivariate (P < .02) analysis. Among the 137 patients who had resected nodules, 57 nodules (41.6%) were cytologically subclassified as nuclear atypia, 75 (54.7%) were classified as architectural atypia, and the remaining 5 exhibited atypical lymphoid cells. Baseline demographics and Subclassifying "Atypical" Thyroid FNACs/Gan et al
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April 2017 ultrasonographic features were available in all patients. These were not significantly different between the former 2 groups, as indicated in Table 2 . Analysis of the final histology results revealed an overall malignant outcome in 37 of 137 (27%) atypical cases. The malignancy rate in cases with nuclear atypia was significantly higher at 36.8% (21 of 57) than that for cases with architectural atypia, which was 14.7% (11 of 75; P < .01) ( Table 3) .
Among the 75 cases of architectural atypia, 9 were FLUS Hurthle. Malignancy was identified in 22.2% (2 of 9) of FLUS Hurthle cases, whereas the other 7 were benign (3 benign oncocytic nodules, 2 Hurthle cell adenomas, and 2 multinodular goiters). All 5 AUS/FLUS lymphoid lesions were malignant on final histology (Table 3) . No repeat FNACs were performed in the AUS/FLUS lymphoid cases, because the patients underwent excision biopsy for flow cytometric and histologic analysis.
There were 6 cases of follicular variant of papillary thyroid carcinoma, including 5 that had an initial FNAC diagnosis of AUS/FLUS with nuclear atypia and 1 that had AUS/FLUS with architectural atypia, as indicated in Table 3 . These cases did not fulfill the diagnostic criteria for noninvasive follicular thyroid neoplasm with papillarylike nuclear features (NIFTP) because of the absence of a capsule or the presence of capsular invasion.
DISCUSSION
The current results yielded an institutional malignancy rate of 27% in lesions labeled as AUS/FLUS using TBSRTC, and papillary thyroid carcinoma was the most common malignant diagnosis. This finding corroborates many other studies suggesting that the malignancy rate in the atypical category is higher than originally thought (Table 4) , 11, [17] [18] [19] [20] [21] [22] [23] [24] Hence, the Bethesda "atypical" category may not adequately address the differential malignancy rates within its subclasses and continues to pose significant diagnostic dilemmas. One of the challenges within this category is the suggested risk of malignancy. According to TBSRTC, the malignancy risk is estimated at 5% to 15%. 7 However, institutional malignancy rates for this category demonstrate ; 4) different methodologies in follow-up studies, with some including cases without surgical resection (Table 4) 25 ; and 5) studies predating the Bethesda system and subsequently adopting this system to retrospectively classify cytology results, possibly including cases that would have been more suitably classified into categories other than AUS/FLUS. 23 Differing patient cohorts may also play a role, because institutions range from population-based clinical facilities to tertiary referral centers. The lack of postsurgical follow-up in a large number of cases further compounds the difficulty obtaining definitive statistical data on the actual malignancy rates. 7, 21, 26 Multiple independent studies have demonstrated that the risk of malignancy for this category is significantly higher than the range predicted by TBSRTC. The average malignancy risk for all studies that considered surgical resection was 34%, as indicated in Table 4 . [9] [10] [11] 13, [17] [18] [19] [20] [21] [22] [23] [24] This discrepancy in the malignancy rate was also highlighted in the revised 2015 ATA guidelines, 15 and the International Panel has recommended adjustments to the risk of malignancy in the "atypical" category in the second edition of TBSRTC.
14 Our findings are in agreement with the modifications to the risk of malignancy for the "atypical" category proposed by the International Panel. There were no NIFTPs among our resected AUS/ FLUS cases. It has been observed that the recent change in terminology and reclassification of NIFTP to a nonmalignant outcome have substantially decreased malignancy rates in FNAC diagnostic categories, especially among the indeterminate nodules. Faquin et al demonstrated a drop in malignant outcomes from 31.2% to 17.6%. 27 It also Subclassifying "Atypical" Thyroid FNACs/Gan et al
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appears to be logical that NIFTPs may be subclassified into the "nuclear atypia" group within AUS/FLUS, which may potentially decrease the malignancy outcome in this subgroup more than in the architectural atypia group. More long-term prospective studies are needed to better assess the impact of this shift in classification. A possible reason for the higher malignancy rate in our institution is the more stringent application of architectural and cytomorphologic criteria for "atypia." The incidence rate of AUS/FLUS is 6.4% in our institution (unpublished data). It is perhaps not surprising that an inverse relation between AUS/FLUS incidence rates and the risk of malignancy has been demonstrated by several groups. [28] [29] [30] According to the current Bethesda system recommendations, this category should be used as a last resort, and the rates should be limited to 7% or fewer of all thyroid FNACs. 7 However, institutions report widely various rates, 31 from 3% 32 to 27.2%, 33 and the recommended rate of 7% may also be revised upward in the second edition of TBSRTC. A possible reason for the various rates of AUS/ FLUS in the literature could be the specimenpreparation method. 23 Chang et al observed that direct smears could lead to confounding factors, including obscuring blood or drying/fixation artifacts, which lead to more FNACs resorting to an AUS diagnosis and hence a higher percentage of AUS. 34 Conversely, others have observed that liquid-based preparations are associated with a significantly higher proportion of inadequate and indeterminate samples. 35, 36 At our institution, direct smears are used, but we did not observe a higher rate of AUS/FLUS. An internal audit of all thyroid FNAC results at our institution in 2011 revealed prevalence rates of 6.4% for AUS/FLUS, 2.8% for follicular neoplasms, 1.4% for suspicious for malignancy, and 2.1% for frank malignancy (unpublished data). The specific Bethesda category prevalence rates of our institution's FNAC results are comparable to those reported in the existing literature. Thus, the reason for our malignancy rate of 27% in AUS/FLUS is more likely to be because of the application of more stringent diagnostic criteria for atypia rather than preparation method.
Another point of discussion is the need for subclassification of the AUS/FLUS category according to the presence of nuclear or architectural atypia, given the differential malignancy rates of the subclasses observed both by us and by several other groups. [10] [11] [12] [13] 16, 20, [23] [24] [25] [26] 32, [37] [38] [39] The International Panel for the second edition of TBSRTC has also recommended further subclassification of this category. Despite this, subclassification is currently still not widely adopted, 15 nor has it been officially endorsed by the 2015 revised ATA guidelines 15 ; therefore, it remains an area of contention. The panel also does not specifically address management guidelines within the subcategories, ie, with or without nuclear atypia.
14
In our study, we subclassified the "atypical" category into nodules with nuclear atypia versus those with standalone architectural atypia (not amounting to follicular neoplasm). Results from a subgroup analysis supported the proposed subclassification, revealing a significantly higher malignancy rate for nuclear atypia than for architectural atypia (36.8% vs 14.7%; P < .01). On the basis of our findings, we now recognize that the "atypical" Bethesda category may not always be considered "low risk," particularly if there is significant nuclear atypia. Thus we propose to subclassify this heterogeneous category based on the presence of nuclear atypia among the follicular cells. The outcome-based evidence supports this proposal, with implications on patient management. Others have also observed that this is true, demonstrating malignancy rates ranging from 32% to 76% in nodules with nuclear atypia versus 10% to 32.6% in nodules with only architectural atypia. 11, 13, 20, [22] [23] [24] [38] [39] [40] The optimal management of patients who have results in the AUS/FLUS category is another gray area, 41 and current management ranges from clinical follow-up, to repeat FNAC, to up-front surgical resection. 42, 43 The recommended management guidelines based on the 2007 TBSRTC are clinical correlation and a repeat FNAC after an appropriate interval, usually after 3 months, because this category represents a "low" risk of malignancy. 17 However, as discussed above, the malignancy risk for this category may fall within or even exceed the original estimated malignancy risk of "follicular neoplasm," which is from 15% to 30%. 7 VanderLaan also reported a malignancy rate of 41.1% (37 of 90 cases) of "atypical" nodules that were resected up front, which further increased to 47.2% after 1 repeat FNAC. 23 Those authors proposed a re-evaluation of the Bethesda recommendation of repeat FNA. We demonstrate a similar trend with an increase in the malignancy rate from 24.1% (33 of 137 cases) to 27% (37 of 137 cases) after up to 3 repeat FNACs. Nevertheless, repeat FNAC did provide some benefit, yielding a more definitive cytologic diagnosis in 67.1% of our cases, with the most common repeat FNAC outcome falling into the benign category (44 of 73; 60.3%). These findings are corroborated by other studies, which have demonstrated more definitive diagnoses in 56% to 80% of repeat FNACs. 9, 17, 18, [44] [45] [46] We observed that the repeat FNAC diagnoses in nodules with architectural atypia alone were more likely to be benign than in those with nuclear atypia (24 of 26, 47 because a significant proportion (23 of 34 [67.6%]) of these had a more definitive diagnosis with repeat FNACs. In contrast, for those who have nodules with nuclear atypia, surgery (hemithyroidectomy) may be considered, given the higher malignancy rate for these patients, 37 ranging in the literature from 32% to 76%, 11, 13, 20, [22] [23] [24] [38] [39] [40] with our rate of 36.8% within range. The role of intraoperative frozen section in the management of AUS/FLUS nodules was not specifically studied in this exercise. However, frozen section may play a potential role, particularly for cases in which the possibility of papillary thyroid carcinoma was raised on cytology. 15 In such cases, intraoperative smears may also prove helpful. Clinical and radiologic correlations 15 can also aid in guiding management decisions for patients with AUS/ FLUS nodules. Our analysis of demographic data revealed no significant difference between benign and malignant nodules in the current study, consistent with others. 48, 49 However, irregularity of margins on ultrasonography was a significant predictor of malignancy on univariate analysis and an independent predictor on multivariate analysis. This is corroborated by other studies as well. 43, 50, 51 Ultrasonographic features thus could be of practical utility in decision making with regard to the appropriate management of patients with AUS/FLUS. The recent rapid advances in the development of molecular markers have provided further options to better define the risk of malignancy for patients with AUS/FLUS. Currently, 3 main molecular panels are available 52 : Afirma (Veracyte), a 167-gene expression classifier that functions as a "rule-out" test with a negative predictive value (NPV) Subclassifying "Atypical" Thyroid FNACs/Gan et al
Cancer Cytopathology
April 2017 of 95%, and ThyroSeq v2.1 and ThyGenX/ThyraMir, which use a combination of genetic alterations as well as gene expressions to define malignancy risk. The latter 2 function as both "rule-in" and "rule-out" tests, because as they have a high NPV and much a higher positive predictive value (PPV) than Afirma at 77% and 68%, respectively. Studies have indicated that these molecular tests have significant diagnostic value for cytologically indeterminate nodules, including AUS/FLUS, [53] [54] [55] and the 2015 revised ATA guidelines also have recognized them as a valid alternative to repeat FNAC in managing indeterminate cases. 15 Nevertheless, molecular interrogation needs to be balanced with cost and availability, and there is currently no single, widely accessible molecular test that can definitively rule in or out malignancy in indeterminate cases. Long-term outcome data are still needed to prove the clinical utility and cost effectiveness of these molecular markers. 15 Thus, knowledge of each institution's malignancy rates for the AUS/FLUS category would be useful in forming the basis of these future studies, because the NPV and PPV of a particular molecular test depend on the local risk of malignancy. 52, 56 There are several limitations to this study. First, it was a retrospective study with possible selection bias, because the malignancy rate was determined based only on patients who had undergone surgery. This can lead to an overestimation, because patients who undergo immediate surgical intervention after a single AUS/FLUS diagnosis are more likely to have had clinical factors that increase the suspicion of malignancy, such as family history, presence of symptoms related to nodules, or radiologic factors. 23, 43 Second, 35.9% of our patients had no further intervention or follow-up, because they left the country, became uncontactable, or died from unrelated causes. This is comparable to the rate reported by other studies in the literature, ranging from 14.7% to 60.3%. 17, 20, 23, 57 Third, we were unable to control patients' treatment choices given a particular FNA result, which could have led to biases in treatment outcomes. 42 Fourth, interobserver and intraobserver variability in ultrasound and FNAC interpretation were not specifically evaluated. Nonetheless, experienced radiologists interpreted all ultrasound findings, senior pathologists from the same department interpreted all FNACs and repeat FNACs based on the standardized TBSRTC, and a single senior pathologist performed the final subclassification of FNAC results and reviewed the histology results.
In conclusion, the malignancy rate on resection for thyroid nodules with a diagnosis of AUS/FLUS was 27% in our cohort. We observed a significantly higher malignancy rate in cases with nuclear atypia (36.8%) than in those with only architectural atypia (14.7%), thus supporting the proposal for subclassification of the "atypical" Bethesda category based on the presence of nuclear atypia. Repeat FNAC was helpful for a more definitive diagnosis in 67.1% of nodules. The only independent clinical predictive factor for malignancy in AUS/FLUS nodules was irregularity of margins on ultrasound evaluation. On the basis of our histologic outcome data, we also note that it may be prudent to re-evaluate management approaches between the subcategories of nuclear versus architectural atypia, with consideration for surgery in cases with nuclear atypia versus repeat FNA in cases with architectural atypia. To better answer these management-related questions, further prospective, large-scale studies are needed to build on what we and others have demonstrated.
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